EP1416914A1 - Dispositif de retention gastrique expansible - Google Patents

Dispositif de retention gastrique expansible

Info

Publication number
EP1416914A1
EP1416914A1 EP01995328A EP01995328A EP1416914A1 EP 1416914 A1 EP1416914 A1 EP 1416914A1 EP 01995328 A EP01995328 A EP 01995328A EP 01995328 A EP01995328 A EP 01995328A EP 1416914 A1 EP1416914 A1 EP 1416914A1
Authority
EP
European Patent Office
Prior art keywords
agents
retention device
gastric retention
gastric
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01995328A
Other languages
German (de)
English (en)
Inventor
James W. Ayres
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon State University
Oregon State
Original Assignee
Oregon State University
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State University, Oregon State filed Critical Oregon State University
Publication of EP1416914A1 publication Critical patent/EP1416914A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dispositifs de rétention gastrique fait à partir de compositions comprenant des matières polymères telles que des polysaccharides, et éventuellement des matières additionnelles telles qu'excipients, produits thérapeutiques et produits de diagnostic, qui restent dans l'estomac de façon prolongée, pendant une durée que l'on peut maîtriser.
EP01995328A 2001-08-16 2001-10-22 Dispositif de retention gastrique expansible Withdrawn EP1416914A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31307801P 2001-08-16 2001-08-16
US313078P 2001-08-16
PCT/US2001/046146 WO2003015745A1 (fr) 2001-08-16 2001-10-22 Dispositif de retention gastrique expansible

Publications (1)

Publication Number Publication Date
EP1416914A1 true EP1416914A1 (fr) 2004-05-12

Family

ID=23214285

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01995328A Withdrawn EP1416914A1 (fr) 2001-08-16 2001-10-22 Dispositif de retention gastrique expansible

Country Status (14)

Country Link
EP (1) EP1416914A1 (fr)
JP (1) JP2005501097A (fr)
KR (1) KR20040032918A (fr)
CN (1) CN1543337A (fr)
BR (1) BR0117123A (fr)
CA (1) CA2456976A1 (fr)
CO (1) CO5670360A2 (fr)
IL (1) IL160363A0 (fr)
MX (1) MXPA04001388A (fr)
NO (1) NO20040611L (fr)
NZ (1) NZ531461A (fr)
PL (1) PL368327A1 (fr)
WO (1) WO2003015745A1 (fr)
ZA (1) ZA200402066B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466808C (fr) * 2001-11-21 2009-01-27 E-Z-Em, Inc. Formulations a utiliser dans les procedures medicales et diagnostiques
WO2005062898A2 (fr) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Absorption amelioree de formes de dosage a liberation modifiee
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
JP2009543886A (ja) * 2006-07-19 2009-12-10 スミスクライン・ビーチャム・コーポレイション ガンマシンチグラフィー評価のために処方物を放射性標識する方法
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
WO2013183058A2 (fr) 2012-06-07 2013-12-12 Tulip Medical Ltd. Dispositif étendu
WO2015083171A1 (fr) 2013-12-05 2015-06-11 Tulip Medical Ltd. Dispositifs et systèmes de rétention pour la libération in-situ d'agents pharmaceutiques actifs
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CN106573015B (zh) 2014-06-11 2021-11-26 麻省理工学院 肠溶弹性体
CN107592803B (zh) 2015-05-01 2021-01-22 麻省理工学院 可触发形状记忆感应装置
EP3364946A4 (fr) 2015-10-23 2019-06-26 Lyndra, Inc. Systèmes à demeure gastriques pour libération prolongée d'agents thérapeutiques et leurs procédés d'utilisation
WO2018064630A1 (fr) 2016-09-30 2018-04-05 Lyndra, Inc. Systèmes de résidence gastrique permettant l'administration prolongée de médicaments de la classe de l'adamantane
CA3086153A1 (fr) * 2017-12-18 2019-06-27 Tris Pharma, Inc. Composition de poudre de medicament a liberation modifiee comprenant des systemes de formation de raft de retention gastrique ayant une liberation de medicament par impulsions de declenchement
TR201914116A2 (tr) * 2019-09-17 2021-04-21 Univ Yeditepe Doğal bi̇yomateryaller i̇le kri̇yojelleri̇n üreti̇m yöntemi̇ ve bu kri̇yojelleri̇n yumuşak doku i̇skelesi̇ veya i̇laç taşiyici si̇stem olarak kullanimi
WO2022195476A1 (fr) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Dispositifs de rétention gastrique pour l'évaluation d'états intragastriques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
EP1003476B1 (fr) * 1997-08-11 2004-12-22 ALZA Corporation Forme galenique d'un agent actif a liberation prolongee adaptee a la retention gastrique
SK285478B6 (sk) * 1998-09-14 2007-02-01 Ranbaxy Laboratories Limited Jednodenná formulácia na orálne podanie na kontrolované uvoľňovanie ciprofloxacínu
JP2000256216A (ja) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd ゲル組成物
AU2001268722B8 (en) * 2000-06-23 2005-09-29 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03015745A1 *

Also Published As

Publication number Publication date
WO2003015745A1 (fr) 2003-02-27
CN1543337A (zh) 2004-11-03
NZ531461A (en) 2008-03-28
MXPA04001388A (es) 2004-05-27
CO5670360A2 (es) 2006-08-31
PL368327A1 (en) 2005-03-21
IL160363A0 (en) 2004-07-25
JP2005501097A (ja) 2005-01-13
KR20040032918A (ko) 2004-04-17
NO20040611L (no) 2004-04-16
ZA200402066B (en) 2005-05-09
CA2456976A1 (fr) 2003-02-27
BR0117123A (pt) 2004-09-28

Similar Documents

Publication Publication Date Title
US20040219186A1 (en) Expandable gastric retention device
US5811126A (en) Controlled release matrix for pharmaceuticals
EP1750717B1 (fr) Compositions pharmaceutiques a liberation controlee presentant une meilleure biodisponibilite
Dehghan et al. Gastroretentive drug delivery systems: A patent perspective
KR100618234B1 (ko) 다공성 입자를 포함하는 제형
Shaha et al. An overview of a gastro-retentive floating drug delivery system
US5582837A (en) Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
EP1416914A1 (fr) Dispositif de retention gastrique expansible
JPH0830007B2 (ja) 徐放性カプセル
WO2003035177A2 (fr) Melanges polymeres optimaux pour comprimes a retention gastrique
AU2002337974A1 (en) Optimal polymer mixtures for gastric retentive tablets
EP1296657A1 (fr) Compositions et forme posologique pour liberation gastrique retardee d'alendronate et/ou d'autres bis-phosphonates
JP2003521507A (ja) ゼロ次薬物放出に接近するシェル−コア剤形
CA2121038C (fr) Preparation orale pour liberation dans le tractus gastro-intestinal inferieur
WO2022200971A1 (fr) Procédé de production de matrices compactes de rétention gastrique pour la libération contrôlée de substances actives et matrices compactes ainsi obtenues
JP4224866B2 (ja) 溶解時間を制御した基剤
JP3122478B2 (ja) 下部消化管放出型経口製剤
AU2002225872A1 (en) Expandable gastric retention device
Katakam et al. Floating drug delivery systems: a review
AU2014368504B2 (en) Gastro-retentive oral pharmaceutical compositions
JPWO2019039420A1 (ja) 医薬組成物粒子とそれを含む口腔内崩壊製剤、医薬組成物粒子の製造方法
Yuganya Design and Evaluation of Gastro Retentive Floating Drug Delivery System of Valsartan.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040218

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080424